The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Aβ). Aβ is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Aβ [1-40], Aβ [1-42], and Aβ [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Aβ [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Aβ antibodies and peptides have been developed as tools for elucidating the biology of AD.
This antibody recognizes human Amyloid β42 at the C-terminus.
KLH-conjugated linear peptide corresponding to the C-terminus of Amyloid β42.
ELISA: A representative lot of MABN12 antibody was used in a titer ELISA. Specificity of Amyloid beta peptide detection is displayed below.
Research Sub Category
Anti-Amyloid β42 Antibody, clone G2-11 detects level of Amyloid β42 & has been published & validated for use in WB, WB, ELISA, IH.
Evaluated by Western Blot on human Alzheimer diseased brain tissue lysate.
Western Blot Analysis: 1 µg/ml of this antibody detected Amyloid β42 in 10 µg of human Alzheimer diseased brain tissue lysate.
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Human Alzheimer diseased brain tissue lysate
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.